# HDM2017

Source: https://onco.cc/drugs/hdm2017/  
OnCo record `hdm2017` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

HDM2017 is an experimental investigational agent whose form is not stated in the registry from Hangzhou Zhongmei Huadong Pharmaceutical in phase 2 trials for colorectal cancer, aimed at MET.

## Summary

HDM2017 is an investigational agent whose form is not stated in the registry developed by Hangzhou Zhongmei Huadong Pharmaceutical. Its target is MET. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in colorectal cancer. The largest, NCT07805551, plans to enrol 220 participants with primary completion expected 2030-08. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: not stated (registered as a drug or biological on ClinicalTrials.gov)
- Mechanism: Investigational agent whose form is not stated in the registry directed at MET, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of HDM2017: https://clinicaltrials.gov/search?intr=HDM2017

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- targets: [MET](https://onco.cc/targets/met/)
- trials: [A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer](https://onco.cc/trials/nct07621159/), [A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer](https://onco.cc/trials/nct07805551/)

---
JSON: https://onco.cc/api/v1/entities/hdm2017.json